Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

Mehta R, et al.  – Research published in Transplantation and Cellular Therapy shows better outcomes for matched unrelated donor and matched sibling donor hematopoietic cell transplantation (HCT) than haploidentical donor HCT when using post-transplant cyclophosphamide for graft-versus-host disease prevention in a single center study.

Battipaglia G, et al. – Research published in Bone Marrow Transplantation finds that less HLA mismatching is associated with better overall survival, non-relapse mortality, and leukemia-free survival when comparing one-antigen mismatched unrelated donor hematopoietic stem cell transplant to haploidentical donor HCT in the presence of post-transplant cyclophosphamide.


John M. Pagel, MD, PhD, Megan Othus, PhD, et al – Barriers to human leukocyte antigen (HLA) typing and cytogenetic testing can significantly impact the overall survival of patients newly diagnosed with acute myeloid leukemia (AML).  In this landmark study, a concerted effort to address those issues and streamline the initiation of donor identification and referral for hematopoietic cell transplant (HCT) consultation in early disease state led to a higher CR1 transplantation rate and improved 2-year overall survival.

Dehn J, et al., Blood – A panel of immunogeneticists and other experts in the field of hematopoietic cell transplantation (HCT) has published updated evidence-based guidelines for the optimal selection of unrelated donors and cord blood units used for transplants.

The updated guidelines make recommendations for both HLA and non-HLA factors to consider in graft selection, including donor availability, donor age, patient sensitivity to HLA antigens, natural killer (NK) cell alloreactivity, and minimum total nucleated cell doses and CD34+ cell doses for cord blood units.


Subscribe to E-News

Receive new research summaries monthly.